Catherine Roe, PhD

Associate Professor of Neurology


Research Interests

  • Preclinical Alzheimer disease
  • CSF and imaging biomarkers of Alzheimer disease
  • Driving performance in older adults with and without preclinical Alzheimer disease
  • Non-cognitive outcomes of Alzheimer disease
  • Cognitive and brain reserve
  • Alzheimer disease and cancer
  • Mood, stress, sensation, and physical abilities in relation to Alzheimer disease

Related Links


2015    Mentor of the Year Award, the Institute of Clinical and Translational Sciences’ Master’s Program in Clinical Investigation, Washington University

2014    Invited lectureship, Preclinical AD Biomarkers are Associated with Poorer Driving Performance: Preliminary Results, International Neuropsychological Society, Seattle, Washington

2014    Invited lectureship, Biomarkers and AD & Relationship between Alzheimer Pathology and Cognitive Reserve, Sociedad de Neurologia Psiquiatria y Neurocirugia, Puerto Varas, Chile

2012    Institute of Public Health Scholar, Washington University

2011    Visiting Scholar, Universidad de Chile

2010    Peer Group Mentoring Program for Women Faculty, Washington University

2010    Invited lectureship, Alzheimer’s and Cognitive Reserve: Effects with Amyloid Imaging, International Neuropsychological Society, Acapulco, Mexico

2010    Invited lectureship, PreMCI, AD, and Cognitive Reserve, Mild Cognitive Impairment Symposium, Miami Beach, Florida

2009    Dorismae and Harvey A. Friedman Award for Excellence in Patient-Oriented Care, Education, or Research on Aging or Aging Issues from the Harvey A. Friedman Center for Aging at Washington University

2007    NIA Butler-Williams Scholars Program (formerly the National Institute on Aging 2007 Summer Institute on Aging Research)

2005    National Alzheimer’s Coordinating Center Junior Investigator Award


  • PhD (Clinical Psychology & Experimental Psychology): Southern Illinois University, Carbondale, IL (1992)
  • Post-doctoral mentored training program (Clinical Investigation): Washington University, St. Louis, MO (2010)

Clinical Interests

Catherine Roe, PhD, is Associate Professor in the Department of Neurology at Washington University School of Medicine. Before coming to WU, Roe did clinical research using very large databases of medical and pharmacy claims at Express Scripts, Inc. Roe holds a patent as Co-inventor of The Assessing Dementia-8 (AD8): The Washington University Dementia Screening Test. In addition to being Associate Editor for the Journal of Alzheimer’s Disease, she is also Associate Editor for BMC Neurology’s Dementias Section, and is an ad hoc reviewer for numerous scientific journals.  Roe is the Principal Investigator of an R01 examining preclinical Alzheimer disease in relation to functional outcomes such as driving, as well as mood, stress, physical abilities, and sensation.


  • Duchek JM, Carr DB, Hunt L, Roe CM, Xiong C, Shah K, Morris JC. Longitudinal Driving Performance in Early-Stage Dementia of the Alzheimer Type.  Journal of the American Geriatrics Society 2003; 51:1342-1347.
  • Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer’s disease and cancer.  Neurology 2005;64:895-898.
  • Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, Miller JP, Storandt M, Morris JC. The AD8: A brief informant interview to detect dementia. Neurology 2005;65:559-564.
  • Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid biomarkers of early stage Alzheimer’s disease predict future dementia in cognitively normal older adults. Archives of Neurology 2007;64:343-349.
  • Roe CM, Xiong C, Miller JP, Morris JC. Education and Alzheimer’s disease without dementia: support for the Cognitive Reserve Hypothesis. Neurology 2007;68:223-228.
  • Roe CM, Mintun MA, D’Angelo G, Xiong C, Grant E, Morris JC. Alzheimer’s and cognitive reserve: variation of education effect with carbon 11-labled Pittsburgh Compound B. Archives of Neurology 2008;65:1467-1471. PMCID: PMC2752218
  • Morris JC, Roe CM, Grant EA, Head D, Storandt M, Goate AM, Fagan AM, Holtzman DM, Mintun MA. PIB Imaging Predicts Progression to Symptomatic Alzheimer’s Disease. Arch Neurol 2009;66:1469-1475.
  • Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, Williams MM, Kopan R, Behrens MI, Morris JC. Cancer linked to Alzheimer’s disease but not vascular dementia. Neurology 2010;74:106-112. PMCID: PMC2809029
  • Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, Mintun MA. APOE genotype predicts Aβ but not tau pathology in cognitively normal aging: amyloid imaging and CSF biomarkers in preclinical Alzheimer’s disease. Annals of Neurology 2010;67:122-131. PMCID: PMC2830375
  • Roe CM, Mintun MA, Ghoshal N, Williams MM, Grant EA, Marcus DS, Morris JC.  Enhanced identification of Alzheimer’s disease using amyloid imaging: proof of concept. Neurology 2010;75:42-48. PMCID: PMC2906402.
  • Roe CM, Fagan AM, Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, Mintun MA, Holtzman DM, Morris JC. Improving CSF Biomarker Accuracy in Predicting Prevalent and Incident Alzheimer’s Disease. Neurology 2011;76(6):501-510. PMCID: PMC3053181.
  • Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TLS, Mintun MA, Holtzman DM, Morris JC. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology 2013;80:1784–1791. PMCID: PMC3719431.
  • Roe CM, Fagan AM, Grant EA, Holtzman D, Morris JC. CSF Biomarkers of Alzheimer’s Disease: “Non-Cognitive” Outcomes. Neurology 2013;81:2028-2031. PMCID: PMC3854826.
  • Masters MC, Morris JC, Roe CM. “Noncognitive” symptoms of early Alzheimer disease. A longitudinal analysis. Neurology 2015;84:617-622.
  • Ingber AP, Hassenstab J, Fagan AM, Benzinger TLS, Grant EA, Holtzman DM, Morris JC, Roe CM. Cerebrospinal fluid biomarkers and reserve variables as predictors of future “non-cognitive” outcomes of Alzheimer disease. Journal of Alzheimer’s Disease 2016;52:1055-1064.
  • Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Angela C, Ott BR, Holtzman DM, Benzinger TLS, Fagan AM, Carr DB, Morris JC. Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance among Cognitively Normal Individuals. Alzheimer’s Disease and Associated Disorders 2016 Apr 28. [Epub ahead of print].
  • Babulal GM, Ghoshal N, Head DM, Vernon EK, Holtzman DM, Benzinger TLS, Fagan AM, Morris JC, Roe CM. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer’s Disease Biomarker Levels. American Journal of Geriatric Psychiatry 2016 Apr 19. pii: S1064-7481(16)30082-3. doi: 10.1016/j.jagp.2016.04.004. [Epub ahead of print].
  • Babulal GM, Traub CM, Webb M, Stout SH, Addison A, Carr DB, Ott BR, Morris JC, Roe CM. Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. F1000Research 2016, 5:2376 (doi: 10.12688/f1000research.9608.1).
  • Ott BR, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, Carr DB, Roe CM. Brain amyloid in preclinical Alzheimer’s disease is associated with increased driving risk. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (In press).
  • Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA,  Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC. Preclinical Alzheimer Disease and Longitudinal Driving Decline. Alzheimer’s & Dementia: Translational Research & Clinical Interventions (In press).